Biosite and MedImmune join forces:
This article was originally published in Clinica
Under an agreement that will last for up to three years, Biosite plans to use its Omniclonal phage display technology to evaluate the diagnostic potential of drug targets that will be provided by MedImmune. In addition to gaining certain diagnostic rights, Biosite will receive development fees upon delivery to MedImmune of target-specific antibodies. MedImmune expects to use Biosite's high affinity antibodies in its discovery research, which focuses on infectious disease, autoimmune disease and cancer, the company says.